Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well you got your answer about what Chan has been doing. You should give him a pat on the back now!
you have no idea what Chan is doing
My point was we have a ton of capacity.
In the last ER call, they stated the new manufacturing facility which is online, can produce $80 million in filters. They have a ton of capacity. They did not break down how many filters that is, but consider they have close to 80% margins, so you can do that math if you want.
No way to know if the cartridge was used on those patients or how far along they were before treatment. Your statement is baseless in this context. The filter removes cytokines to prevent the storm and relating organ damage. It is not a cure, it allows the body to fight the good fight.
Roger that. All good.
Filters don't cure, that is not their intention. They are used to clear out cytokines, allowing the body to heal without it cascading into a cytokine storm resulting in organ failure. It is used in conjunction with other modes of treatment. It gives patients a fighting chance.
It would seem CTSO’s “Homodefend plasma filter” could play an important role in Covid trhttps://www.reuters.com/article/us-china-health-hospital-idUSKBN20B1M6eatment. This is in addition to the lead Cytokine filter. There are two products that can play a role with Covid.
https://www.nationalgeographic.com/science/2020/02/here-is-what-coronavirus-does-to-the-body/
If you have a Twitter account or FB I recommend posting that this:
$CTSO Cytosorbents blood filter can help here. It filters out cytokines to prevent the storm and the cascading effects. IE. organ failure.
Sure and if the qtr is strong and we hit profitability then we should go to all-time highs. Just a few weeks ago people were commenting that they wish they bought at these prices. IMO the position of the company has never been better. Take advantage of these discounts.
You are spot on Burnttoast247. I have run several sales organizations and started companies. Never do you open a window into internal sales operations. Chan provides enough.
You must be joking, Dr. Chan has just pulled off an amazing feat. He got the German government to pay for a trial and got FDA approval to move onto Refresh 2. In addition, he has added Dr. Juno to the board.
All of us want the price higher, but Dr. Chan has achieved so much with so little. You should be thankful.
Great job Dr.Chan, you did exactly what you said you would do by the end of the year. Looking forward to profitability in 2018. What a great Christmas present!
Edwards Lifesciences is another possibility, they are a huge player in valve replacement technology. Based out of Irvine Ca.
I just got this email from Cytosorbents. This is what we are hoping for!
Congratulations to Novartis and Dr. Carl June at the University of Pennsylvania and CHOP on the unanimous vote by the FDA advisory committee to approve the first CAR T-cell immunotherapy for leukemia. Based on our positive data in treating HLH, a close cousin to cytokine release syndrome (CRS) - a common and potentially life-threatening complication of CAR T-cell therapy, an expected approval of Novartis' therapy later this year could open new paths to fast track approval of CytoSorb in the US.
https://wwwusnews.com/news/top-news/articles/2017-07-13/t-cell-cancer-therapy-holds-promise-longer-term-results-await?src=usn_gp
http://www.fiercebiotech.com/biotech/safety-priority-for-novartis-car-t-as-adcomm-docs-released
Agree Bertha, the company is making very important and meaningful moves. Frustrating price action for sure. The foundation for sustained positive price action is under way IMO.
Agree, inflammation is an issue with cancer, and so many other diseases.
Thanks Bertha, appreciate the posts. Keep it up. Could care less about the others on here that constantly post negative content all the time. I don't need them to save me from myself. Just interested in $CTSO's market moves and science progress.
Bertha, Please keep it up, I look forward to your insights. Much appreciate. Thank you!
I thought I read a post that someone was going to email Dr. Chan about the issuance. Anyone get a response?
Thanks in advance
You are correct, this is getting bought. That is a great sign.
IMO, this is the perfect time to raise cash, prior to refresh release. There will be no questions about how they will pay for the trial going into the reveal. The needed raise is out of the way, the market will reward Dr. Chan.
To those talking about partners not contributing to a trial,there is no way to know. However, nothing comes without strings attached. I hope that costs are shared and perhaps the shares were priced lower to sweeten the pot for the partner. If there is no partner participation on financing a trial, I am fine with that,$CTSO maintains control.
The reimbursement in Germany is huge, we just had our first $Million dollar hospital in Germany, more will follow. This is the blueprint. It is playing out as the filter become SOC. Other countries will follow.
Stocking orders are now set by contract with very significant partners. This is a very good setup. It is harder to see if you've been holding for a long time ( I have). I am bullish on this move.
I view this as a buying opportunity. I am sure others will disagree. That's what makes a market. The company needs to move forward, this is the best way IMO.
The addition of Dr. Carl June to the $CTSO Scientific Advisory board is HUGE. He is a giant in Immunotherapy. Dr. Chan has really made a fantastic move here. This should raise the interest in the investment and medical community about Cytosorbents. Such a great move. Congrats Dr. Chan!
Agree, I value and look forward to Bertha's comments. Bertha please continue the great work.
Immunexpress wins FDA clearance for sepsis tests that could save billions
http://www.bizjournals.com/seattle/blog/health-care-inc/2017/02/immunexpress-fda-clearance-septicyte-sepsis-tests.html?ana=e_ptl_hc&u=xG6E9MeVM4fp1qZM3FR7OcbIYtN&t=1487889725&j=77474621
Thanks for talking this down prior to ER, allows me to buy more at a better price before the pop!
That is exactly what we hope for with the filters! Great report. Exactly what the doctor ordered. Pun intended.
CytoSorbents Corp.'s PT raised by Maxim Group to $10.00. marketbeat.com/stocks/NASDA... $CTSO.
First of many!
This Veterinary care move is brilliant. Adds a whole new $Billion market to CTSO, will also bring in new investors and partners that may help pay for trials.
I think your response is very inadequate, I invite other board members to comment on this.
Pearsby,
Safety recalls of the drugs you mentioned are immaterial and not relevant here and you know that.
It is up to you to provide links and evidence that support your claim that Cytosorbents' products are not safe.
I provide the following to support my position:
Thousands of treatments and no known safety issues have come to light that I am aware of.
CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 17,000 human treatments to date.
Cytosorbents also was granted it's own reimbursement codes in Germany. This would never happen if safety issues existed.
Pearsby, just as on the Yahoo board, you chose to poison this one with false, misleading tripe. The medical community & the FDA has deemed these products safe.
We know you hate the company & the stock, but at least stick to facts, not lies & innuendo.
The most important thing to me on this dedicated reimbursement code is that this would not have happened with out data. There is data out there that was compelling enough to support this.
That is what we have been waiting for. This should be the inflection point Chan has been speaking about. Now other countries can fall in line. A way forward can been seen towards the goal of becoming SOC.
It certainly is good news. We needed it. Reimbursement is key to becoming SOC. Good to see a post from you under the Bertha alias. Appreciate your posts, please keep it up.